Literature DB >> 717574

Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.

J Kane, F Quitkin, A Rifkin, D F Klein.   

Abstract

Forty-nine schizophrenic outpatients stabilized on oral antipsychotic medication and procyclidine received 12.5 mg or 18.75 mg of fluphenazine enanthate or fluphenazine decanoate and were examined for extrapyramidal side effects one and two weeks later. Extrapyramidal side effects were present in 30 patients (61%) but were clinically significant in only 11 (22%). Fluphenazine enanthate produced more clinically significant extrapyramidal symptoms, particularly akathisia, than did fluphenazine decanoate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 717574     DOI: 10.1176/ajp.135.12.1539

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  3 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Drug-induced akathisia: a review.

Authors:  R Ball
Journal:  J R Soc Med       Date:  1985-09       Impact factor: 5.344

3.  Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.

Authors:  A C Altamura; S H Curry; S Montgomery; D H Wiles
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.